Case File
efta-efta00304890DOJ Data Set 9OtherNON-DISCLOSURE AGREEMENT
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta00304890
Pages
2
Persons
0
Integrity
No Hash Available
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
NON-DISCLOSURE AGREEMENT
Effective this 4th day of April 2013 (the "Effective Date") DEKA Research & Development Corp., a
New Hampshire, USA corporation with offices at 340 Commercial St., Manchester, NH, 03101,
USA (-DEW), and Jeffrey Epstein, with an address at
(hereafter "RECIPIENT), agree as follows:
1. On the terms stated in this Agreement, DEKA intends to disclose Confidential Information
to RECIPIENT for RECIPIENT to use for the sole purpose of evaluating a potential
business relationship with DEKA (the "Purpose").
2. As used in this Agreement, "DEKA Confidential Information" means non-public
information about DEKA and DEKA's affiliates' business, products, and ongoing
development
projects,
including
without limitation
business
plans,
drawings,
specifications, designs, engineering data, manufacturing data, marketing data, and/or
prototypes. DEKA may disclose DEKA Confidential Information under this Agreement in
oral, visual or written form.
3. RECIPIENT shall maintain the confidence of all DEKA Confidential Information that
RECIPIENT receives under this Agreement. RECIPIENT shall not, directly or indirectly,
disclose and/or reveal to third parties the DEKA Confidential Information except when
expressly authorized in writing by DEKA.
4. RECIPIENT shall not use any DEKA Confidential Information except for the Purpose
identified above.
5. RECIPIENT will use at least the same degree of care to safeguard DEKA Confidential
Information that RECIPIENT uses to safeguard RECIPIENT's own confidential
information, and in any event not less than a reasonable degree of care. RECIPIENT
shall limit access to DEKA's Confidential Information to RECIPIENT's own employees,
agents or representatives who have a direct 'need to know" for the Purpose and who are
bound by written agreement with RECIPIENT to maintain the confidentiality by terms of
nondisclosure no less restrictive than those contained herein.
6. RECIPIENT shall, upon DEKA's request, return to DEKA, all written or otherwise
recorded DEKA Confidential Information (including copies, if any).
7. This Agreement shall become effective when signed by both parties and shall apply to
disclosures made from Effective Date through one year after the Effective Date.
RECIPIENT's obligations to maintain the confidence of DEKA Confidential Information
shall survive the termination of this Agreement for a period extending to five (5) years
from the date of disclosure under this Agreement.
8. This Agreement shall not apply to any DEKA Confidential Information that (i) becomes a
matter of public knowledge or otherwise enters the public domain through no fault of
RECIPIENT, or (ii) is disclosed to RECIPIENT by a third party, as shown by
RECIPIENT'S business records, provided that such third party was not breaching any
agreement or any confidential relationship in doing so and otherwise properly obtained
such information.
9. If RECIPIENT is compelled by any court or governmental order to reveal DEKA
Confidential Information, RECIPIENT shall promptly notify DEKA and, if requested by
DEKA, RECIPIENT shall cooperate with DEKA to attempt to obtain a protective order.
Provided RECIPIENT has complied with the foregoing, RECIPIENT's compliance with
such a court or governmental order shall not be a violation of this Agreement.
10. RECIPIENT shall promptly notify DEKA if RECIPIENT becomes aware of any
RECIPIENT disclosure or misuse of DEKA Confidential Information in violation of this
Agreement.
11. DEKA does not hereby grant RECIPIENT any license or other rights by disclosure of
DEKA Confidential Information hereunder. DEKA makes no representation or warranty
to RECIPIENT regarding DEKA Confidential Information disclosed hereunder.
EFTA00304890
12. This Agreement is the entire agreement of the parties with respect to disclosures of
DEKA Confidential Information hereunder. This Agreement may only be modified by a
written amendment signed by both parties.
13. Delaware, USA law governs this Agreement. In addition to any remedies available at
law, DEKA shall be entitled to equitable remedies, including without limitation specific
performance and temporary and permanent injunctions, in the event of any breach or
threatened breach of this Agreement.
IN WITNESS WHEREOF DEKA Research & Development Corp. and RECIPIENT have
signed this NON-DISCLOSURE AGREEMENT.
DEKA Research & Development Corp.
By:
Stephen Hermans, Corporate Counsel
Date: April
, 2013
Jeffrey Epstein
Date: April_, 2013
EFTA00304891
Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.